Trial Profile
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Lymphoma; Nervous system neoplasms; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 15 Jun 2019 This trial has been completed in France as per European Clinical Trials Database record.
- 07 Jun 2018 Status changed from active, no longer recruiting to discontinued.
- 01 Feb 2018 Planned End Date changed from 16 Jan 2018 to 9 Jul 2018.